SCHEMBL4021223

SCHEMBL4021223

Cc1cccc(C2[C@@H](C(=O)c3ccccc3)CN(CC(=O)N3CCN(C)CC3)C[C@@H]2C(=O)c2ccccc2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TERT O14746 1/20 0.39
POLB P06746 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MAPK1 P28482 3/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTGS2 P35354 1/20 0.37
EPHX2 P34913 1/20 0.37
EGFR P00533 1/20 0.36
TYMS P04818 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021226 1.00 KMT2A (0.42) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4772583 0.94 MEN1 (0.39) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4021968 0.92 ALDH1A1 (0.44) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4023694 0.92 ALDH1A1 (0.44) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4021972 0.92 ALDH1A1 (0.44) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4020218 0.89 MAPT (0.39) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4020222 0.89 MAPT (0.39) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4022026 0.89 MEN1 (0.45) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4022022 0.89 MEN1 (0.45) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL4780151 0.85 KCNH2 (0.43) KMT2AMEN1ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 KMT2A 2820/4885MEN1 77/4885LMNA 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.